Breathonix has developed a breath test to detect COVID-19 within a minute in-situ (on-site), achieving an accuracy above 90% at a recent pilot clinical trial involving 180 patients.
Following a successful trial at the National Centre for Infectious Diseases (NCID), the company said on Thursday (Oct 29) that it is currently in discussions with the Health Ministry (MOH) to deploy its breathalyser tests in trials at public locations in the coming months.
Universities are hotbeds for ideas, where pioneering solutions that tackle society’s challenges are often seeded and even commercialised. It was […]
With its proprietary breath sampling device and data analysis algorithms, their technology analyses one’s “exhaled breath”, which provides an extremely precise way to detect diseases by analysing volatile organic compounds (VOCs).
In particular, instead of swab tests, new breath analyser devices developed by the National University of Singapore’s Nanoscience and Nanotechnology Institute that can detect lung cancer and tuberculosis can be re-purposed for the mass screening of COVID-19 for real-time and on-site analysis.
Dr Jia said: "I thought I was going to end up as a research scientist, but NUS made me see the potential of converting my idea into an actual invention that can help save lives."